IVF-ET sikluslarında ovaryen stimulasyon için rekombinant folikül stimulan hormon ve human menopozal gonadotropin kullanımının sonuçlar üzerine etkisi
Amaç: Ovulasyon indüksiyonu yapılan IVF-ET olgularında rekombinant folikul stimulant hormon (rFSH) ve human menopozal gonadotropin (hMG) kullanımının in-vitro fertilizasyon sonuçları üzerine etkisinin araştırılması. Materyal ve Metod: Nisan 2001-Mayıs 2002 tarihleri arasında Tüp Bebek Ünitesinde ovulasyon indüksiyonu yapılan kadınların dosyalarının retrospektif olarak incelenmesi ile hMG kullanılan 72 ve rFSH kullanılan 100 olgu analiz edilmiştir. Bulgular: Embryo transferi yapılan sikluslarda, gebelik oranlan hMG grubunda % 27.3 ve rFSH grubunda % 20.2 olarak saptanmıştır. Bu fark istatistik! olarak anlamlı değildir( p=0.35) hMG ve rFSH arasında elde edilen matür oosit, indüksiyon süresi, kullanılan total gonadotropin dozu ve fertilizasyon oranları ile ilişkili olarak hiçbir istatistiki anlamlı fark bulunmamıştır. Sonuç: Klinik gebelik oranları açısından her iki stimulasyon rejimi arasında anlamlı fark bulunmadığı saptandı.
Recombinant FSH versus human menopausal gonadotropins for ovarian stimulation in IVF cycles: Analysis of outcomes
Objective: To analyze the results of using rFSH and hMG for ovarian stimulation in in vitro fertilization cycles. Material and method: A retrospective analysis of all the treatment cycles between April 2001 and May 2002 were performed. Treatment with hMG was used for 72 patients, whereas 100 patients were treated with rFSH. Results: Of the cycles with embryo transfer, the pregnancy rates were 27.3 % and 20.2 % in the hMGand the rFSH groups, respectively. This difference is not statistically significant (p=0.35). No significant differences were found with regard to the number of mature oocytes, the duration of stimulation, the total amount of gonadotropin used and the fertilization rates. Conclusion: It's found that there was no significant difference between two stimulation regiments in terms of the clinical pregnancy rate.
___
- 1. Agrawal R., Holmes J., Jacobs HS. Follicle
stimulating hormone or human menopausal
gonadotropin for ovarian stimulation in in vitro
fertilization cycles: a meta analysis. Fertil Steril 2OO0:
73; 338-343
- 2. Daya S, Gunby J., Highes EG. et al. Randomized
controlled trial of follicle stimulating hormone
versus human menopausal gonadotropin in in vitro
fertilization outcome. Hum Reprod., 1995: 10;1392-1396
3. Levy D.P., Navarro J.M., Schattman G.L., Davis OJC Rosenwaks Z. The role of LH in ovarian stimulation. Exogenous LH: lets design the future. Hum Reprod. 2000:11; 2258-2265.
4. Giudice F., Crisci C.,Eshkol A. et al. Composition of commercial gonadotropin preparations extracted from human post menopausal urine: characterization of non-gonadotropin proteins. Hum Reprod. l994:9;2291-2299
5. Schats R., Sutter PD., Bassil S., Kremer J.A.M.,set
al. Ovarian stimulation during assisted reproduction
treatment: a comparison of recombinant and highly
purified urinary human FSH. Hum reprod
- 2000;15:1691-1697
- 6. Check J.H. HMG is possibly superior to
recombinant FSH for IVF. Hum Reprod
- 2001;16:2473-2477
7. Ng EHY, Lau EYL., Yeung WSB and Ho PC. HMG is as good as human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Hum Reprod 2001:16; 319-325
8. Imthurn B., Macas E., Rosselli M. et al. Nuclear
maturity and oocyte morphology after stimulation
with highly purified follicle stimulating hormone
compared to human menopausal gonadotropin. Hum
Reprod.l996:ll;2387-2391
9. Jacob S., Drudy L., Conroy R.et al. Outcome from
consecutive in vitro fertilization/intracytoplasmic
sperm injection attemps in the final group treated with
urinary gonadotropins and the first group treated with
recombinant follicle stimulating hormone. Hum
Reprod. 1998: 13; 1783-1787
10. Strehler E, Abt M., El Danasoouri I. et al. Impact
of recombinant follicle stimulating hormone and
human menopausal gonadotropins on in vitro
fertilization outcome. Fertil Steril 2001: 75; 332-336